Sotorasib: all 50 studies that test it

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT07012031Phase 1/2
• Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic AdenocarcinomaRecruitingNCT06892054Phase 1
• A Study of Sotorasib in People With Brain TumorsRecruitingNCT06807619Phase 1
• A Study of Sotorasib in People With Non-Small Cell Lung CancerRecruitingNCT06582771Phase 2
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingNCT06252649Phase 3
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06249282Phase 1
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
• Ladarixin With Sotorasib in Advanced NSCLCRecruitingNCT05815173Phase 1
• Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12CRecruitingNCT05631249Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to SotorasibNot yet recruitingNCT05451056Phase 2
• Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapyRecruitingNCT05398094Phase 2
• Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With ComorbiditiesRecruitingNCT05311709Phase 2
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2
• A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy VolunteersCompletedNCT05497557Phase 1Results posted
• VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung CancerTerminatedNCT05374538Phase 1Results posted
• A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 TabletsCompletedNCT05327491Phase 1Results posted
• Tarlox and Sotorasib in Patients With KRAS G12C MutationsTerminatedNCT05313009Phase 1/2Results posted
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationCompletedNCT05198934Phase 3Results posted
• Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 2Results posted
• A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy ParticipantsCompletedNCT05048784Phase 1Results posted
• Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy ParticipantsCompletedNCT05045638Phase 1Results posted
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentTerminatedNCT04933695Phase 2Results posted
• Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic ImpairmentCompletedNCT04887064Phase 1Results posted
• AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).CompletedNCT04380753Phase 1Results posted
• Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).CompletedNCT04303780Phase 3Results posted
• A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06333678Phase 2
• Rivaroxaban Sotorasib Interaction StudyCompletedNCT06314763Phase 4
• AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnNCT06068153Phase 2
• A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy ParticipantsWithdrawnNCT06061523Phase 1
• A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabActive, not recruitingNCT05993455Phase 2
• Ladarixin With Sotorasib in Advanced NSCLC - Phase IIWithdrawnNCT05815186Phase 2
• A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05599828Phase 1
• Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy ParticipantsCompletedNCT05598281Phase 1
• Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05581992Phase 1
• A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05581758Phase 1
• A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male SubjectsCompletedNCT05578859Phase 1
• A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy ParticipantsCompletedNCT05577624Phase 1
• A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy ParticipantsCompletedNCT05571163Phase 1
• A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05568082Phase 1
• Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy ParticipantsCompletedNCT05550129Phase 1
• SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationTerminatedNCT05480865Phase 1
• Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLCWithdrawnNCT05400577Phase 2
• Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas CancerWithdrawnNCT05251038Phase 1/2
• A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisWithdrawnNCT05180422Phase 1/2
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
• A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompletedNCT04959981Phase 1
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT04625647Phase 2

← Sotorasib overview